Foote JE - Search Results

1

Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.

Kennelly MJ, Lemack GE, Foote JE, Trop CS. Kennelly MJ, et al. Among authors: foote je. Urology. 2009 Oct;74(4):741-5. doi: 10.1016/j.urology.2009.05.008. Epub 2009 Jul 22. Urology. 2009. PMID: 19628264

2

Puboprostatic sling repair for treatment of urethral incompetence in adult neurogenic incontinence.

Daneshmand S, Ginsberg DA, Bennet JK, Foote J, Killorin W, Rozas KP, Green BG. Daneshmand S, et al. J Urol. 2003 Jan;169(1):199-202. doi: 10.1016/S0022-5347(05)64067-0. J Urol. 2003. PMID: 12478135

3

Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial.

Chancellor MB, Bennett C, Simoneau AR, Finocchiaro MV, Kline C, Bennett JK, Foote JE, Green BG, Martin SH, Killoran RW, Crewalk JA, Rivas DA. Chancellor MB, et al. Among authors: foote je. J Urol. 1999 Jun;161(6):1893-8. J Urol. 1999. PMID: 10332461 Clinical Trial.

4

Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia.

Chancellor MB, Gajewski J, Ackman CF, Appell RA, Bennett J, Binard J, Boone TB, Chetner MP, Crewalk JA, Defalco A, Foote J, Green B, Juma S, Jung SY, Linsenmeyer TA, MacMillan R, Mayo M, Ozawa H, Roehrborn CG, Shenot PJ, Stone A, Vazquez A, Killorin W, Rivas DA. Chancellor MB, et al. J Urol. 1999 May;161(5):1545-50. J Urol. 1999. PMID: 10210393 Clinical Trial.

5

Reversible clinical outcome after sphincter stent removal.

Chancellor MB, Rivas DA, Watanabe T, Bennett JK, Foote JE, Green BG, Killorin EW, MacMillan R. Chancellor MB, et al. Among authors: foote je. J Urol. 1996 Jun;155(6):1992-4. J Urol. 1996. PMID: 8618306 Clinical Trial.

6

Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele.

Hernandez RD, Hurwitz RS, Foote JE, Zimmern PE, Leach GE. Hernandez RD, et al. Among authors: foote je. J Urol. 1994 Nov;152(5 Pt 1):1582-5. doi: 10.1016/s0022-5347(17)32480-1. J Urol. 1994. PMID: 7933209 Clinical Trial.

7

Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application.

Gajewski JB, Chancellor MB, Ackman CF, Appell RA, Bennett J, Binard J, Boone TB, Chetner MP, Crewalk JA, Defalco A, Foote J, Green B, Juma S, Jung SY, Linsenmeyer TA, Macaluso JN Jr, Macmillan R, Mayo M, Ozawa H, Roehrborn CG, Schmidt J, Shenot PJ, Stone A, Vazquez A, Killorin W, Rivas DA. Gajewski JB, et al. J Urol. 2000 Mar;163(3):773-6. doi: 10.1016/s0022-5347(05)67801-9. J Urol. 2000. PMID: 10687974

8

Terazosin for vesicosphincter dyssynergia in spinal cord-injured male patients.

Bennett JK, Foote J, El-Leithy TR, Saleem MD, Green B, Archer CL, Gray M. Bennett JK, et al. Mol Urol. 2000 Winter;4(4):415-20. Mol Urol. 2000. PMID: 11156710

9

Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.

Foote J, Glavind K, Kralidis G, Wyndaele JJ. Foote J, et al. Eur Urol. 2005 Sep;48(3):471-7. doi: 10.1016/j.eururo.2005.05.009. Eur Urol. 2005. PMID: 15990219

10

Continent diversion and bladder augmentation in spinal cord-injured patients.

Bennett JK, Gray M, Green BG, Foote JE. Bennett JK, et al. Among authors: foote je. Semin Urol. 1992 May;10(2):121-32. Semin Urol. 1992. PMID: 1636071 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters